{"id":388,"date":"2018-01-16T09:17:43","date_gmt":"2018-01-16T17:17:43","guid":{"rendered":"https:\/\/2020dev.rakuten-med.com\/?p=388"},"modified":"2022-04-19T21:26:18","modified_gmt":"2022-04-20T04:26:18","slug":"aspyrian-therapeutics-inc-announces-successful-advances-in-rm-1929-clinical-development-in-recurrent-head-and-neck-cancer-including-fast-track-designation-granted-by-the-fda-initiation-of-clinical-s","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/","title":{"rendered":"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018"},"content":{"rendered":"<p>Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RM-1929&#8230;<strong><a href=\"https:\/\/www.prnewswire.com\/news-releases\/aspyrian-therapeutics-inc-announces-successful-advances-in-rm-1929-clinical-development-in-recurrent-head-and-neck-cancer-including-fast-track-designation-granted-by-the-fda-initiation-of-clinical-studies-in-japan-and-plans-to-300583615.html\" target=\"_blank\" rel=\"noopener noreferrer\">click here to continue reading<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-388","1":"press_releases","2":"type-press_releases","3":"status-publish","5":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-20T04:26:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2018\\\/01\\\/16\\\/388\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2018\\\/01\\\/16\\\/388\\\/\",\"name\":\"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"datePublished\":\"2018-01-16T17:17:43+00:00\",\"dateModified\":\"2022-04-20T04:26:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2018\\\/01\\\/16\\\/388\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2018\\\/01\\\/16\\\/388\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2018\\\/01\\\/16\\\/388\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/","og_locale":"en_US","og_type":"article","og_title":"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.","og_description":"Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/","og_site_name":"Rakuten Medical - To conquer cancer.","article_modified_time":"2022-04-20T04:26:18+00:00","og_image":[{"width":1500,"height":900,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/","url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/","name":"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018 - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"datePublished":"2018-01-16T17:17:43+00:00","dateModified":"2022-04-20T04:26:18+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2018\/01\/16\/388\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"SUCCESSFUL ADVANCES IN RM-1929 CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER, INCLUDING FDA FAST TRACK DESIGNATION INITIATION OF CLINICAL STUDIES IN JAPAN, AND PLANS TO START PIVOTAL STUDIES, WHICH WILL INCORPORATE THE EVALUATION OF ANTI-CANCER IMMUNE RESPONSES, IN EARLY 2018"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases\/388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/press_releases"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/4"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}